百龙创园 20260227 摘要 2025 年膳食纤维总销量超 4.8 万吨，其中聚葡萄糖约 2.1 万吨，抗性 糊精约 2.7 万吨。抗性糊精销量同比增长接近 50%，聚葡萄糖因产能受 限同比下降约 20%。产品结构调整是聚葡萄糖销量下滑主因，并非需求 端走弱。 2025 年阿洛酮糖成交量略高于 1 万吨，同比增长不到 30%，单价同比 下降 10%-20%，主要受上游原料价格影响。但受益于新产线投用和原 料向上游延伸，阿洛酮糖毛利率仍提升不到 10 个百分点。 阿洛酮糖相关酶制剂已获批，产品预计 3 月底前落地。预计 2026 年对 收入和利润有贡献，但具体规模不确定。饮品端或率先导入阿洛酮糖， 因国内无糖饮品市场体量更大，且易实现不含糖。 公司预计阿洛酮糖销量中期增速可维持在 20%-30%甚至更高。当前全 球用量约 3 万吨，未来市场空间大。价格是主要制约因素，需健康意识 提升、下游厂商推动和消费者教育。 新增 2-3 万吨膳食纤维产能项目已进入调试投产阶段，预计二季度开始 贡献收入和利润，四季度左右可能满产。产品结构将根据市场需求决定， 若抗性糊精需求增长快，其增速可能显著快于聚葡萄糖。 Q&A 外 ...

来源：新浪证券-红岸工作室 2月27日，百龙创园跌1.41%，成交额1.84亿元，换手率1.75%，总市值105.63亿元。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 5、根据2023年4月28日公告：公司作为全球重要的益生元和膳食纤维产品生产商，产品远销美国、加拿 大、俄罗斯、韩国等国家和地区。目前公司已和国内外众多知名企业建立了良好的合作关系，积累了大 量优质客户资源，并能为客户定制生产符合其口感或产品指标的定制产品。目前公司品牌客户包括 Quest Nutrition、Halo Top、One Brands、General Mills、娃哈哈、农夫山泉、蒙牛、伊利、旺旺、王老 吉、达利、脑白金、汤臣倍健、康宝莱、东阿阿胶、新希望、红星美羚、均瑶健康、南方黑芝麻、双 汇、科迪乳业、雅士利、飞鹤乳业等国内外大中型知名企业，覆盖了食品、饮料、乳制品、保健品、医 ...

（来源：千龙网） 出台专项支持政策、搭建关键共性服务平台、营造产业生态……以微元合成为代表，昌平区的合成生物 制造产业规模正在加速扩展。截至目前，落户昌平的合成生物制造企业数量为146家。在生物基新材 料、胶原蛋白、生物育种、气体发酵等合成生物制造细分领域，均有企业持续深耕。 目前，昌平合成生物制造产业已经进入集群化发展新阶段。昌平区相关负责人透露了新年新目标：2026 年，昌平区力争新落地10个合成生物制造标志性项目，实现合成生物制造产业收入突破100亿元。接下 来，昌平区将从区域领先迈向全国引领，逐渐形成重要影响力和号召力，打造合成生物制造创新策源地 和产业引领区。 春节假期刚过，在未来科学城合成生物制造产业创新孵化区及转化加速区内，一批微生物"工人"已经开 工，不知疲倦地高效产出阿洛酮糖、饲料蛋白等"生物造"产品。与2025年同期相比，在北京昌平区落户 的合成生物制造企业数量增长近七成，产业规模持续壮大，集聚效应日益凸显。 从实验室里的毫克级样品，到工业生产线上的吨级产品，园区内，微元合成生物技术（北京）有限公司 已成功实现甘露醇、阿洛酮糖、木糖醇等产品的商业化落地，聚焦人类营养、动物营养、日化原料、药 ...

走进实验室，整齐排列的一个个生物反应器，就是一座座"无声工厂"，肉眼不可见的微生物作为"新型 工人"，一呼一吸之间就能生产各类合成生物产品，堪称"生物造万物"。刘波介绍，最近，"新型工 人"的研发也在持续进行，公司菌种库内保存的微生物样本已达十余万种，随着研发的推进，这个数字 仍在不断增长。 出台专项支持政策、搭建关键共性服务平台、营造产业生态……以微元合成为代表，昌平区的合成生物 制造产业规模正在加速扩展。截至目前，落户昌平的合成生物制造企业数量为146家。在生物基新材 料、胶原蛋白、生物育种、气体发酵等合成生物制造细分领域，均有企业持续深耕。 目前，昌平合成生物制造产业已经进入集群化发展新阶段。昌平区相关负责人透露了新年新目标：2026 年，昌平区力争新落地10个合成生物制造标志性项目，实现合成生物制造产业收入突破100亿元。接下 来，昌平区将从区域领先迈向全国引领，逐渐形成重要影响力和号召力，打造合成生物制造创新策源地 和产业引领区。 本报讯（记者 刘苏雅）春节假期刚过，在未来科学城合成生物制造产业创新孵化区及转化加速区内， 一批微生物"工人"已经开工，不知疲倦地高效产出阿洛酮糖、饲料蛋白等"生物造"产 ...

异动分析 代糖概念+参股银行+人民币贬值受益+专精特新+海峡两岸 1、公司生产的健康甜味剂产品主要为阿洛酮糖，阿洛酮糖是在自然界中天然存在但含量极少的一种稀 有单糖，其甜味及口感与蔗糖相当类似或接近，但其热量却远低于蔗糖，对于肥胖以及糖尿病患者是一 种理想的蔗糖代替物。 2、2024年半年报，公司持有山东禹城农村商业银行股份有限公司 5.14%股份。 3、根据2024年年报，公司海外营收占比为60.62%，受益于人民币贬值。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 来源：新浪证券-红岸工作室 2月24日，百龙创园跌0.12%，成交额1.78亿元，换手率1.71%，总市值103.62亿元。 主力没有控盘，筹码分布非常分散，主力成交额5348.55万，占总成交额的9.62%。 5、根据2023年4月28日公告：公司作为全球重要的益生元和膳食纤维产品生产商，产品远 ...

Core Viewpoint - Sanyuan Biotech is facing multiple dynamics including the final ruling of anti-dumping duties in the U.S., progress on the allulose project, and the promotion of new products [1] Group 1: Stock Recent Trends - The U.S. Department of Commerce has announced a final ruling on anti-dumping and countervailing investigations regarding Chinese erythritol products, with Sanyuan Biotech facing a comprehensive execution tax rate of 93.58% for exports to the U.S. This ruling will take effect upon publication in the Federal Register and may have a lasting impact on the company's U.S. market operations [2] - The European Union will impose a 156.7% anti-dumping tax on Chinese erythritol starting January 2025, lasting for five years. The company has responded by launching blended products, indicating that the impact of this event may persist [2] Group 2: Company Project Progress - The company's annual production project for 20,000 tons of allulose has completed the construction of the main engineering and equipment installation for the remaining 10,000 tons of capacity. The next steps will involve organizing environmental assessments and gradually advancing production. This project aims to enrich the product portfolio, but the production schedule and benefits are subject to approval processes and market demand [3] Group 3: Business Development Status - Sanyuan Biotech is continuously providing samples of Reb M to domestic and international potential customers and conducting application experiments. Some customers have already incorporated it into their reduced-sugar product formulations. Tagatose, as a key new functional sugar, is in a critical phase of market promotion and industrial application [4] Group 4: Company Status - The company will hold a board meeting on February 4, 2026, to review the proposal for convening the first extraordinary shareholders' meeting of 2026, with further arrangements to be announced [5]

Group 1 - The company is actively providing samples of Reb M to domestic and international potential clients, with some clients already incorporating it into their sugar-reduction product formulations [2] - Tagatose, as a key focus for the company, is currently in a critical phase of market promotion and industrial application, with steady progress being made [2] - The company has utilized Reb M in the formulation of products containing erythritol and allulose, enhancing product quality and market competitiveness [2]

Core Viewpoint - The final ruling on anti-dumping and countervailing duties ("double anti") against Chinese erythritol products has been announced, with the leading company, Sanyuan Biotech, facing a maximum combined tax rate of 93.58%, significantly impacting its market competitiveness in the U.S. [1][2] Group 1: Tax Rates and Impact - Sanyuan Biotech has been assigned a countervailing duty rate of 8.63% and an anti-dumping duty rate of 84.95%, leading to a total tax rate of 93.58% [1][2] - The company did not qualify for separate rate status, resulting in a unified tax rate of 184.26% for other exporters, although this is a reduction from the initial rate of 450.64% [2] - The high tax rates are expected to diminish Sanyuan's cost competitiveness in the U.S. market, leading to potential order reductions and market share loss [2][3] Group 2: Market Dynamics and Alternatives - The U.S. market for sweeteners is significant, with 30%-40% of beverages being imported, indicating ongoing demand despite the tariff challenges [3] - Sanyuan Biotech can explore alternative market strategies, such as changing product forms to bypass tariffs or utilizing third-party channels for U.S. market entry [4] - The company is also developing alternatives to erythritol, such as allulose, which is projected to be a strategic sweetener with lower calories and a taste profile similar to sucrose [5] Group 3: Future Prospects and Innovations - Sanyuan Biotech is focusing on technological innovation to extend its product offerings beyond traditional sugar alcohols, which are already cost-effective due to mature production processes [5] - The company aims to tap into emerging markets in Southeast Asia, India, the Middle East, and South America as part of its growth strategy [4][5]

Core Viewpoint - The final ruling on anti-dumping and countervailing duties ("double reverse") against Chinese erythritol products has been announced, with Tsinghua Biotech facing a maximum combined tax rate of 93.58%, significantly impacting its market competitiveness in the U.S. [2][3] Group 1: Tax Rates and Impact - Tsinghua Biotech's final anti-subsidy rate is 8.63%, and the anti-dumping rate is 84.95%, leading to a total tax rate of 93.58% [2][3] - The company did not qualify for separate rate status, resulting in a nationwide unified tax rate of 184.26% for other producers/exporters without separate rate qualifications [3] - The high tax rates are expected to weaken Tsinghua Biotech's cost competitiveness in the U.S. market, leading to potential order reductions and market share loss [3] Group 2: Market Demand and Supply Dynamics - The U.S. is projected to have a per capita sugar and sweetener consumption of approximately 121 pounds (about 55 kg) in 2025, with erythritol being a popular choice due to its natural and zero-calorie properties [5] - Global demand for erythritol is expected to reach 238,000 tons in 2024, with a compound annual growth rate (CAGR) of 22% from 2020 to 2024, indicating strong market demand [5] - The global erythritol market is forecasted to reach $2.63 billion by 2030, with a growth rate of 21.0% during the 2024-2030 period [5] Group 3: Industry Competition and Challenges - The introduction of new production capacities in 2022 has led to an imbalance in the erythritol market, resulting in increased competition and a risk of low-quality products displacing higher-quality ones [6] - Analysts note that erythritol is not a high-barrier product, and ongoing innovations may highlight its limitations [7] Group 4: Strategic Alternatives - Tsinghua Biotech can potentially circumvent the high tariffs by altering product forms, such as selling processed erythritol products directly to consumers [8] - The company is exploring third-party channels and overseas production to maintain market access in the U.S. [8] - Tsinghua Biotech is also developing alternatives like allulose, which is gaining global recognition and is expected to expand its market significantly [9]

Investment Rating - The industry rating is "Overweight" [3] Core Insights - The report highlights the ongoing active research in life sciences and the rapid integration of biotechnology into economic and social development, providing innovative solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [3][4]. Industry Performance - The Huazhong Synthetic Biology Index increased by 0.11% to 1278.44 during the week of February 2-6, 2026, outperforming the Shanghai Composite Index by 1.39 percentage points and the ChiNext Index by 3.40 percentage points [4]. - The report notes that the synthetic biology sector is experiencing a policy dividend, with Shenzhen proposing up to 100 million yuan in support for R&D efforts in the field [8]. Company Developments - Beijing Huaguan Bio completed a multi-hundred million yuan C-round financing to enhance its R&D and production capabilities in the pharmaceutical and health sectors [32]. - Dejin Bio secured several million yuan in A-round financing to advance its recombinant botulinum toxin clinical research and international expansion [33]. - The report mentions that Impossible Foods is leveraging technology to reshape the plant protein market [11]. Market Dynamics - The report indicates that the synthetic biology sector is witnessing a surge in financing, with nearly a hundred companies completing new funding rounds since 2025 [31]. - The top five companies in the synthetic biology sector by stock performance during the week were Pingtan Development (+12%), Jinbo Bio (+12%), Huaxi Bio (+12%), Shandong Heda (+10%), and Yaxiang Co. (+10%) [17]. Policy and Regulatory Developments - The Ministry of Industry and Information Technology announced 35 examples of non-grain bio-based materials, marking a significant step towards establishing a new green development framework [7]. - The National Health Commission approved 22 new food items, including a significant breakthrough in domestic human milk oligosaccharides (HMOs) production [7]. Research and Innovation - Tsinghua University has initiated a national key R&D project focused on the intelligent design principles of efficient microbial chassis cells, aiming for breakthroughs in both fundamental theory and application demonstration [9]. - The report highlights the strategic cooperation between Tianjin University and China National Petroleum Corporation to expand efforts in synthetic biology and related fields [9].